The Kerala High Court has directed the government to evaluate the affordability of Ribociclib, a breast cancer drug, under Section 100 of the Patents Act. While the court declined to impose immediate price caps, the move signals potential regulatory scrutiny over patented medication costs. Patients and investors are now monitoring the government's next steps as this process currently lacks a fixed timeline for completion.
The Kerala High Court has issued a directive requiring the government to assess the affordability of Ribociclib, a targeted therapy used for metastatic breast cancer. This ruling follows a legal petition originally filed in 2022, which argued that the high cost of the drug creates an accessibility barrier for many patients. At the time the petition was initiated, the cost of a 21-day treatment cycle was reported at approximately ₹58,140, a figure that the court acknowledged creates significant financial strain on middle-class households.
Understanding Section 100 of the Patents Act
The court’s decision centers on the interpretation of Section 100 of the Patents Act, 1970. This legal provision grants the government the authority to use an invention for the purposes of the state. By mandating an evaluation of the drug's affordability, the court has officially recognized the government’s power to intervene when essential medical treatments are deemed inaccessible due to pricing. However, the bench stopped short of ordering immediate price controls or direct intervention, choosing instead to initiate a formal data collection and assessment process by the authorities.
Clinical Distinctions in Cancer Care
A critical part of the court’s observation involved the medical necessity of Ribociclib compared to other alternatives. The ruling clarified that Ribociclib is not clinically interchangeable with Palbociclib, another medication often used in similar cancer treatments. While Palbociclib is available from several manufacturers in India at lower price points, the court determined that these alternatives do not serve the same therapeutic function for all patients. This distinction is vital as it prevents the availability of other, lower-cost drugs from being used as a justification to avoid reviewing the pricing of the more expensive Ribociclib.
Regulatory and Investor Context
For investors and the broader pharmaceutical sector, the ruling highlights the ongoing tension between protecting patent rights and ensuring public access to life-saving medicines. The use of Section 100 as a regulatory tool could set a precedent for how the government manages the affordability of other patented drugs. This adds a layer of regulatory uncertainty for multinational pharmaceutical companies that hold patents on high-cost treatments in India. If the government’s assessment finds the drug unaffordable, it may lead to further discussions on compulsory licensing or other government-led interventions.
Next Steps for Monitorables
Because the judgment does not include a specific reporting mechanism or a hard deadline for the government to complete its assessment, the timeline for any actual price relief remains unclear. Patients and industry watchers will now look for updates from government health authorities regarding the data collection process. If the government decides against using its powers under Section 100 after the review, further legal challenges could emerge. Investors in the pharmaceutical sector may also track this case to understand the government’s future approach to drug pricing and patent usage.